What the Human Evidence on BPC-157 Actually Contains

I am listing these in full because the list being short is the entire point.

1. Phase 1, healthy male volunteers, 2002. 24 healthy men, PL-14736 (the pharmaceutical designation for BPC-157) given as a rectal enema at up to 2 mg/kg daily for 8 days. Reported as safe and well tolerated; the most frequent complaints were headache and flatulence.^[2][4]

2. The only randomised controlled trial, 2005. 53 patients with mild-to-moderate ulcerative colitis randomised 1:1 to an 80 mg rectal enema daily or placebo for two weeks, 46 completing. This is the strongest study in the entire human literature on this compound — and it exists only as a conference abstract. FDA's assessment of it is direct: "The data presented for this study are therefore inadequate to support the efficacy and safety of BPC-157," because "details such as the primary endpoint, inclusion criteria, and statistical methods are lacking." FDA adds that the abstract does not even state how many of the 53 received the drug.^[2]

3. Knee pain, 2021. A retrospective chart review at a private clinic: 17 patients treated, 16 reached by telephone afterwards, 12 of whom received BPC-157 alone — 4 mg injected into the knee joint, usually once, without ultrasound guidance. 14 of 16 reported improvement. Outcomes were a self-reported 0–10 pain score and self-reported sleep and mobility. No control group, no objective measure, mixed diagnoses, and only four patients had any pre-treatment MRI. The authors say so themselves: "Measurements were all subjective; no objective testing was performed to verify their improvements."^[5]

4. Interstitial cystitis, 2024. An open-label pilot in 12 women, 10 mg instilled into the bladder during a single cystoscopy. No control group.^[2]

5. The intravenous safety pilot, 2025. Two people — a 58-year-old man and a 68-year-old woman — given IV BPC-157 over three days, 10 mg then 20 mg, with bloodwork and vital signs monitored. No control group, no efficacy endpoint, and both participants had already been receiving IV BPC-157 before they enrolled. No changes were seen on the markers tested and no side effects were reported; the authors call for larger studies to confirm safety.^[6]

That is the complete set. Roughly 81 people, across 23 years.

This is the finding I would most want a patient to know, and it is the one that gets lost.

Of those five studies: two used a rectal enema, one an intra-articular knee injection, one an intravesical instillation, and one intravenous infusion.

Zero used subcutaneous injection. Zero used oral, nasal or transdermal administration. FDA states this in writing and adds that there are no human pharmacokinetic data for any of those routes — meaning nobody has published what dose produces what blood level, how long it lasts, or how much reaches anything.^[2]

Subcutaneous injection in the abdomen is how BPC-157 is almost universally sold and used. There is no published human study of it. Not a negative study — no study.

A systematic review published in 2025 searched PubMed, Cochrane and Embase from inception to June 2024. It identified 544 articles, screened 393 after removing duplicates, and included 36: 35 preclinical studies and one clinical study.^[3]

Its conclusions, verbatim:

"No clinical safety data were found."

"The in-human safety of BPC-157 was not assessed in the included studies and thus remains unknown."

"Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety."

The review is also fair about the preclinical side: it says BPC-157 "shows promise for promoting recovery from musculoskeletal injuries," on the strength of animal work. That is an honest statement of where the evidence is — promising in animals, essentially unexamined in people.

One correction, since I have cited this review before and cited it wrongly: it is in HSS Journal, not the American Journal of Sports Medicine. I had the venue wrong in internal notes and want the record straight here.

FDA searched its adverse event reporting system for BPC-157 through 4 December 2025. The search returned three reports, all involving injectable BPC-157: injection-site redness and swelling in someone also taking thymosin; shortness of breath with no further detail; and hyperpigmentation with darkening of the gums after re-exposure to a BPC-157/TB-500 product. FDA's own comment: "it is unclear whether these AEs were attributable to BPC-157."^[2]

Three reports, over more than a decade of widespread grey-market use, is not reassuring and it is not alarming. It is uninformative. Nobody is systematically following the people using this, so nothing is being systematically reported. The absence of harm reports in an unobserved population is the same kind of absence as the absence of benefit data.

FDA's forward-looking concerns are about what hasn't been ruled out rather than what has been seen: potential immunogenicity for injected and nasal routes, peptide-related impurities and characterisation difficulties, limited toxicology, and no carcinogenicity data at all.^[2] Its summary sentence is the one I would hold onto: the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans."^[7]

Three facts, all checkable on primary sources, that cut against most of what circulates.

BPC-157 is not on FDA's 503A Bulks List, and it is not in Category 1, 2 or 3. It sits in a separate table of substances "previously in category 2 … withdrawn by the nominators" — the nominations were pulled by the people who made them, which is not the same as FDA clearing anything.^[7] FDA's July 2026 briefing document states that the agency proposed BPC-157 not be included on the list, in both free-base and acetate forms.^[2]

FDA's advisory committee met on 23–24 July 2026 and discussed BPC-157 for ulcerative colitis, with two separate votes — one for the free base, one for the acetate. Press reporting says the committee voted in favour, by narrow margins, against FDA scientists' own advice. FDA has published no minutes, no transcript and no vote record. Advisory committee recommendations are, in FDA's own words, non-binding.^[8]

The 14 October policy is a notice under White House review, not a rule. Its text is not public. Which peptides it covers, which routes, and on what conditions are all unknown.^[1] Nothing has changed yet, and when it does change it will be enforcement discretion — a statement about what FDA will not pursue — rather than approval.

In Canada, none of this is the operative question. Health Canada's advisory of 9 April 2026 names BPC-157 first among seized unauthorized peptides, states that "In Canada, peptides are generally regulated as prescription drugs," and says plainly: "Do not buy or use these products."^[9] An Ontario physician is also bound by CPSO's Prescribing Drugs policy, which states that physicians must not prescribe drugs not approved for use in Canada, with narrow exceptions for authorized clinical trials and the Special Access Programme.^[10] Whatever the FDA does, that is the position here.

I am not telling you BPC-157 does not work. The animal literature is genuinely interesting, and a compound with 35 preclinical studies behind it is not nothing.

I am telling you that if someone describes BPC-157 as well-tolerated, or safe, or studied, you can now ask which study they mean — and that the answer is five small ones, about 81 people, none of them using the route in the syringe. That is worth knowing before weighing it against the rest of a longevity plan.

That is a reasonable thing to accept for yourself with your eyes open. It is not a reasonable thing to be told is settled.